Cardiopulmonary exercise responses in patients with non-ischemic heart failure and a mildly reduced ejection fraction
Source : https://www.futuremedicine.com/doi/10.2217/fca-2021-0135
Background: The cardiopulmonary response to exercise in patients with heart failure exhibiting a mildly reduced ejection fraction (41%≤EF≤49%) remains unclear. Materials & methods: A total of 193 consecutive patients with...
Conclusion: Measurements of grip strength and blood pressure during exercise are useful predictors of prognoses in patients with non-ischemic and mildly reduced EF.
Exercise Training in Heart failure with Preserved and Reduced Ejection Fraction: A Systematic Review and Meta-Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35674912/
ET significantly improves exercise capacity and quality of life in both HFpEF and HFrEF patients. In HFpEF patients, ET significantly improved an important index of diastolic function, with significant improvements...
Conclusions: The benefit of empagliflozin on cardiac outcomes and decline of eGFR is preserved across the wide range of baseline NT-proBNP and hs-cTnT evaluated. Empagliflozin modestly reduces NT-proBNP in HFpEF.
Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35642772/
Heart failure with mildly reduced ejection fraction (HFmrEF) is associated with comparable poor outcomes as other subtypes of heart failure and remains a medical unmet need due to the paucity...
Conclusion/Relevance: Current limited evidence suggests that SGLT2is might be a favourable treatment modality for patients with HFmrEF to reduce hospitalization for heart failure and CV mortality. This conclusion needs to be further supported by clear HFmrEF subgroup analysis of the existing trials. Further outcome trials involving sufficient...
SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35652305/
1 Department of Woman and Child's Health, University of Padova, Padova, Veneto, Italy. 2 Department of Pediatrics, Yale University, New Haven, Connecticut. 3 Department of Medicine, University of Maryland School...
Relevance: Insulin-resistant diabetes in Rabson-Mendenhall syndrome (RMS) is relatively unresponsive to first-line antidiabetic treatments, including metformin and insulin. We report 2 patients with RMS treated with 2 different sodium-glucose cotransporter inhibitors 2: empagliflozin in an 11-year-old boy and dapagliflozin in a 12-year-old...
Masked Primary Hyperparathyroidism by Empagliflozin Use
Source : https://www.cureus.com/articles/76945-masked-primary-hyperparathyroidism-by-empagliflozin-use
Sodium-glucose cotransporter-2 inhibitors are drugs that regulate blood sugar by decreasing glucose reabsorption from the proximal renal tubules. Primary hyperparathyroidism masked by empagliflozin is very rare and only a few...
Relevance: Sodium-glucose cotransporter-2 inhibitors are drugs that regulate blood sugar by decreasing glucose reabsorption from the proximal renal tubules. Primary hyperparathyroidism masked by empagliflozin is very rare and only a few cases are reported in the literature. We report a case of a 57-year-old man with a known history of diabetes...